FBT
First Trust NYSE Arca Biotechnology Index Fund

FBT$151.10
$-0.12
(-0.08%)
As of 3:59:57 PM EDT | 9/19/18  |  Market Closed

FBT Trading Data

Open

$151.17

Low Price

$150.7

High Price

$152.08

Previous Last Price

$151.22

Bid Size

$150.48 X 600

Ask Size

$153.88 X 600

FBT Portfolio Data

AUM

$2,237,020

Shares

14,800

PE Ratio

18.62

Price / Book Ratio

5.74

Expense Ratio

0.56

Net Asset Value

$151.15

Volume

Volume

57,300

Avg. Volume (YDT)

84,834

Dollar Volume

$7,176,837

Weekly Avg. Volume

59,260

Monthly Avg. Volume

74,670

Quarterly Avg. Volume

114,072

FBT Fund Description

The First Trust NYSE Arca Biotechnology Index Fund is and exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index. The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics. The index is rebalanced quarterly based on closing prices on the third Friday in January, April, July and October to ensure that each component stock continues to represent approximately equal weight in the index.

FBT Chart

FBT Summary

Fund Family

First Trust Portfolios

Tracks This Index

First Trust NYSE Arca Biotechnology Index Fund

Inception Date

2006-06-19

Asset Class

Equity

Asset Class Size

Biotech

FBT Classification

Region (General)

Global

Region (Specific)

Sector

Health Care

Equity Index

Leveraged Family

FBT Holdings

Top 10 Holdings

Intercept Pharmaceuticals Inc. ( ICPT )

4.26%

Bio-Techne Corporation ( TECH )

4.24%

Nektar Therapeutics ( NKTR )

4.03%

Neurocrine Biosciences Inc. ( NBIX )

3.82%

IQIVA Holdings Inc. ( IQV )

3.79%

Illumina Inc. ( ILMN )

3.76%

Seattle Genetics Inc. ( SGEN )

3.65%

Amgen Inc. ( AMGN )

3.55%

Regeneron Pharmaceuticals Inc. ( REGN )

3.54%

Charles River Laboratories International Inc. ( CRL )

3.5%

Total FBT Holdings

Total Holdings: 31

Intercept Pharmaceuticals Inc. ( ICPT )
4.26%
Bio-Techne Corporation ( TECH )
4.24%
Nektar Therapeutics ( NKTR )
4.03%
Neurocrine Biosciences Inc. ( NBIX )
3.82%
IQIVA Holdings Inc. ( IQV )
3.79%
Illumina Inc. ( ILMN )
3.76%
Seattle Genetics Inc. ( SGEN )
3.65%
Amgen Inc. ( AMGN )
3.55%
Regeneron Pharmaceuticals Inc. ( REGN )
3.54%
Charles River Laboratories International Inc. ( CRL )
3.5%
Ionis Pharmaceuticals Inc. ( IONS )
3.49%
Celgene Corporation ( CELG )
3.45%
QIAGEN N.V. ( QGEN )
3.41%
United Therapeutics Corporation ( UTHR )
3.39%
Ultragenyx Pharmaceutical Inc. ( RARE )
3.35%
Vertex Pharmaceuticals Incorporated ( VRTX )
3.34%
Incyte Corporation ( INCY )
3.26%
BioMarin Pharmaceutical Inc. ( BMRN )
3.24%
Grifols S.A. (ADR) ( GRFS )
3.22%
Intrexon Corporation ( XON )
3.19%
Gilead Sciences Inc. ( GILD )
3.17%
Biogen Inc. ( BIIB )
3.14%
Alnylam Pharmaceuticals Inc. ( ALNY )
2.97%
FibroGen Inc. ( FGEN )
2.94%
Alexion Pharmaceuticals Inc. ( ALXN )
2.93%
Alkermes Plc ( ALKS )
2.88%
ACADIA Pharmaceuticals Inc. ( ACAD )
2.81%
Agios Pharmaceuticals Inc. ( AGIO )
2.66%
bluebird bio Inc. ( BLUE )
2.56%
Exelixis Inc. ( EXEL )
2.51%
First Trust NYSE Arca Biotechnology Index Fund ( FBT )
0%

FBT Technicals

Alpha

-4.04

Beta

1.76

Leverage

Long

Standard Deviation

9.43

FBT Dividends

Dividend Date

2015-09-23

Latest Dividend

0.02

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

FBT Performance

YTD Return

21.3%

1 Year Return

23.6%

3 Year Return

44.36%

5 Year Return

131.75%

10 Year Return

534.31%

FBT Related Articles

Alkermes FDA Refusal: Biotech ETFs Dragged Down

Alkermes FDA Refusal: Biotech ETFs Dragged Down

Biotechnology stocks and biotech ETFs were among the worst performing areas of the markets Monday as Alkermes (NasdaqGS: ALKS) shares plunged after the U.S. food and Drug Administration refused to…

Biotech ETFs Pop on Celgene, Juno Deal

Biotech ETFs Pop on Celgene, Juno Deal

Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand its cancer treatment profile. Among the best performing biotech-related ETFs, the…

Why Trump Can Boost Biotech ETFs

Why Trump Can Boost Biotech ETFs

In the months leading up to last week’s presidential election, it was clear that perhaps no other sector and the relevant ETFs were caught in political crossfire on par with…